Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KNSA
KNSA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KNSA News
Kiniksa Pharmaceuticals CFO Sells Shares Amid Strong Performance
3d ago
NASDAQ.COM
Kiniksa Executive Sells Shares, Retains Significant Stake
3d ago
Fool
Futures Drop as March Jobs Report Surprises
Apr 03 2026
Yahoo Finance
Stock Market Rises Strongly Despite Soaring Oil Prices
Apr 03 2026
Yahoo Finance
Stock Market Rises Strongly Despite Soaring Oil Prices
Apr 03 2026
Yahoo Finance
Kiniksa to Speak at TD Cowen Health Conference
Feb 25 2026
Yahoo Finance
Kiniksa Pharmaceuticals Q4 2025 Earnings Highlights
Feb 24 2026
seekingalpha
Kiniksa Pharmaceuticals Q4 2025 Earnings Report
Feb 24 2026
seekingalpha
Kiniksa Reports Strong 2025 Financials with 62% Growth in ARCALYST Sales
Feb 24 2026
Newsfilter
Kiniksa Pharmaceuticals Set to Announce Q4 Earnings
Feb 23 2026
seekingalpha
Kiniksa Reports $677.5M in 2025 ARCALYST Revenue, 62% Growth
Jan 12 2026
Globenewswire
Kinaset Therapeutics Closes $103 Million Series B Financing to Advance Inhaled Asthma Treatment
Jan 11 2026
Businesswire
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Nov 19 2025
NASDAQ.COM
Kiniksa Pharmaceuticals Executive Offloads Shares Valued at $1,962,781, Recent SEC Filing Reveals
Oct 22 2025
Yahoo Finance
Analysis Indicates VBK Could Reach $342
Oct 22 2025
NASDAQ.COM
Wells Fargo Keeps Overweight Rating on Kiniksa Pharmaceuticals and Increases Price Target to $45
Sep 25 2025
Benzinga
Show More News
